Role of lutein supplementation in the management of age-related macular degeneration: Meta-analysis of randomized controlled trials

Ophthalmic Research

Volumn 52, Issue 4, 2014, Pages 198-205

  Wang, Xin ^a,b   Jiang, Caihui ^a   Zhang, Ying ^a   Gong, Yan ^a   Chen, Xiaofei ^a   Zhang, Maonian ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Chinese People's Liberation Army General Armaments Department Command Huang Si Clinics   (China)

Author keywords

Lutein; Macular degeneration; Macular pigment optical density; Randomized controlled trials; Visual acuity

Indexed keywords

PLACEBO; XANTHOPHYLL; VISUAL PIGMENT;

AGE RELATED MACULAR DEGENERATION; ARTICLE; ASSESSMENT OF HUMANS; DIET SUPPLEMENTATION; DISEASE CONTROL; DRUG EFFICACY; HUMAN; JADAD SCALE; MACULAR PIGMENT OPTICAL DENSITY; META ANALYSIS; OPTICAL DENSITY; PATIENT RISK; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VISUAL ACUITY; MACULAR DEGENERATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

DIETARY SUPPLEMENTS; HUMANS; LUTEIN; MACULAR DEGENERATION; MACULAR PIGMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL ACUITY;

EID: 84910097546     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000363327     Document Type: Article

References (45)

1. Congdon N, O'Colmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P; Eye Diseases Prevalence Research Group: Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-485.
2. National Eye Institute: Age-related macular degeneration. Statistics and data. http://www. nei.nih.gov/eyedata/amd.asp (accessed July 29, 2013).
3. Friedman DS, O'Colmain BJ, Muñoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J; Eye Diseases Prevalence Research Group: Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004; 122: 564-572.
4. Beatty S, Murray IJ, Henson DB, Carden D, Koh H, Boulton ME: Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 2001; 42: 439-446.
5. Zeimer M, Dietzel M, Hense HW, Heimes B, Austermann U, Pauleikhoff D: Profiles of macular pigment optical density and their changes following supplemental lutein and zeaxanthin: new results from the LUNA study. Invest Ophthalmol Vis Sci 2012; 53: 4852-4859.
6. Landrum JT, Bone RA, Joa H, Kilburn MD, Moore LL, Sprague KE: A one year study of macular pigment modification: the effect of 140 days of lutein supplement. Exp Eye Res 1997; 65: 57-62.
7. Palozza P, Krinsky NI: Antioxidant effects of carotenoids in vivo and in vitro: an overview. Methods Enzymol 1992; 213: 403-420.
8. Khachik F, Bernstein PS, Garland DL: Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Invest Ophthalmol Vis Sci 1997; 38: 1802-1811.
9. Mangels AR, Holden JM, Beecher GR, Forman MR, Lanza E: Carotenoid content of fruits and vegetables: an evaluation of analytic data. J Am Diet Assoc 1993; 93: 284-296.
10. Landrum JT, Bone RA, Kilburn MD: The macular pigment: a possible role in protection from age-related macular degeneration. Adv Pharmacol 1997; 38: 537-556.
11. Hammond BR Jr, Johnson EJ, Russell RM, Krinsky NI, Yeum KJ, Edwards RB, Snodderly DM: Dietary modification of human macular pigment density. Invest Ophthalmol Vis Sci 1997; 38: 1795-1801.
12. Bone RA, Landrum JT, Guerra LH, Ruiz CA: Lutein and zeaxanthin dietary supplements raise macular pigment density and serum concentrations of these carotenoids in humans. Bone J Nutr 2003; 133: 992-998.
13. Dawczynski J, Jentsch S, Schweitzer D, Hammer M, Lang GE, Strobel J: Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study. Graefes Arch Clin Exp Ophthalmol 2013; 251: 2711-2723.
14. Berendschot TT, Goldbohm RA, Klopping WA, van de Kraats J, van Norel J, van Norren D: Influence of lutein supplementation on macular pigment, assessed with two objective techniques. Invest Ophthalmol Vis Sci 2000; 41: 3322-3326.
15. Rosenthal JM, Kim J, de Monasterio F, Thompson DJ, Bone RA, Landrum JT, de Moura FF, Khachik F, Chen H, Schleicher RL, Ferris FL 3rd, Chew EY: Dose-ranging study of lutein supplementation in persons aged 60 years or older. Invest Ophthalmol Vis Sci 2006; 47: 5227-5233.
16. Mares-Perlman JA, Fisher AI, Klein R, Palta M, Block G, Millen AE, Wright JD: Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol 2001; 153: 424-432.
17. Snellen EL, Verbeek AL, Van Den Hoogen GW, Cruysberg JR, Hoyng CB: Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol Scand 2002; 80: 368-371.
18. Gale CR, Hall NF, Phillips DI, Martyn CN: Lutein and zeaxanthin status and risk of agerelated macular degeneration. Invest Ophthalmol Vis Sci 2003; 44: 2461-2465.
19. Moeller SM, Parekh N, Tinker L, Ritenbaugh C, Blodi B, Wallace RB, Mares JA; CAREDS Research Study Group: Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol 2006; 124: 1151-1162.
20. Delcourt C, Carriere I, Delage M, Barberger-Gateau P, Schalch W: Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Invest Ophthalmol Vis Sci 2006; 47: 2329-2335.
21. SanGiovanni JP, Chew EY, Clemons TE, Ferris FL 3rd, Gensler G, Lindblad AS, Milton RC, Seddon JM, Sperduto RD; Age-Related Eye Disease Study Research Group: The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study: AREDS Report No. 22. Arch Ophthalmol 2007; 125: 1225-1232.
22. Mares-Perlman JA, Brady WE, Klein R, Klein BE, Bowen P, Stacewicz-Sapuntzakis M, Palta M: Serum antioxidants and age-related macular degeneration in a population-based casecontrol study. Arch Ophthalmol 1995; 113: 1518-1523.
23. Flood V, Smith W, Wang JJ, Manzi F, Webb K, Mitchell P: Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2002; 109: 2272-2278.
24. Simonelli F, Zarrilli F, Mazzeo S, Verde V, Romano N, Savoia M, Testa F, Vitale DF, Rinaldi M, Sacchetti L: Serum oxidative and antioxidant parameters in a group of Italian patients with age-related maculopathy. Clin Chim Acta 2002; 320: 111-115.
25. van Leeuwen R, Boekhoorn S, Vingerling JR, Witteman JC, Klaver CC, Hofman A, de Jong PT: Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 2005; 294: 3101-3107.
26. Dasch B, Fuhs A, Schmidt J, Behrens T, Meister A, Wellmann J, Fobker M, Pauleikhoff D, Hense HW: Serum levels of macular carotenoids in relation to age-related maculopathy: the Muenster Aging and Retina Study (MARS). Graefes Arch Clin Exp Ophthalmol 2005; 243: 1028-1035.
27. Cardinault N, Abalain JH, Sairafi B, Coudray C, Grolier P, Rambeau M, Carre JL, Mazur A, Rock E: Lycopene but not lutein nor zeaxanthin decreases in serum and lipoproteins in age-related macular degeneration patients. Clin Chim Acta 2005; 357: 34-42.
28. Chow E, Hankinson SE, Rosner B, Willet WC, Colditz GA: Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. Am J Clin Nutr 2008; 87: 1837-1843.
29. Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013; 309: 2005-2015.
30. Age-Related Eye Disease Study 2 (AREDS2) Research Group, et al: Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol 2014; 132: 142-149.
31. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
32. Beck RW, Moke PS, Turpin AH, Ferris FL III, Sangiovanni JP, Johnson CA, Birch EE, Chandler DL, Cox TA, Blair RC, Kraker RT: A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol 2003; 135: 194-205.
33. Murray IJ, Makridaki M, van der Veen RL, Carden D, Parry NR, Berendschot TT: Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: the CLEAR study. Invest Ophthalmol Vis Sci 2013; 54: 1781-1788.
34. Huang YM, Yan SF, Ma L, Zou ZY, Xu XR, Dou HL, Lin XM: Serum and macular responses to multiple xanthophyll supplements in patients with early age-related macular degeneration. Nutrition 2013; 29: 387-392.
35. Ma L, Yan SF, Huang YM, Lu XR, Qian F, Pang HL, Xu XR, Zou ZY, Dong PC, Xiao X, Wang X, Sun TT, Dou HL, Lin XM: Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early agerelated macular degeneration. Ophthalmology 2012; 119: 2290-2297.
36. Richer S, Devenport J, Lang JC: LAST II: differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry 2007; 78: 213-219.
37. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J: Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004; 75: 216-230.
38. Weigert G, Kaya S, Pemp B, Sacu S, Lasta M, Werkmeister RM, Dragostinoff N, Simader C, Garhofer G, Schmidt-Erfurth U, Schmetterer L: Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2011; 52: 8174-8178.
39. Johnson EJ, Chung HY, Caldarella SM, Snodderly DM: The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation. Am J Clin Nutr 2008; 87: 1521-1529.
40. Ma L, Dou HL, Wu YQ, Huang YM, Huang YB, Xu XR, Zou ZY, Lin XM: Lutein and zeaxanthin intake and the risk of age-related macular degeneration: a systematic review and meta-analysis. Br J Nutr 2012; 107: 350-359.
41. Garcia-Layana A, Recalde S, Alamán AS, Robredo PF: Effects of lutein and docosahexaenoic acid supplementation on macular pigment optical density in a randomized controlled trial. Nutrients 2013; 5: 543-551.
42. Richer SP, Stiles W, Graham-Hoffman K, Levin M, Ruskin D, Wrobel J, Park DW, Thomas C: Randomized, double-blind, placebo- controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: the Zeaxanthin and Visual Function Study (ZVF) FDA IND #78, 973. Optometry 2011; 82: 667-680.e6
43. Arnold C, Winter L, Fröhlich K, Jentsch S, Dawczynski J, Jahreis G, Böhm V: Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial. JAMA Ophthalmol 2013; 131: 564-572.
44. Seddon JM, Willett WC, Speizer FE, Hankinson SE: A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 1996; 276: 1141-1146.
45. Johnson EJ: Obesity, lutein metabolism, and age-related macular degeneration: a web of connections. Nutr Rev 2005; 63: 9-15.